Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
QLS12004
i
Other names:
QLS12004
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Qilu Pharma
Drug class:
Undefined mechanism
Related drugs:
‹
BL0020 (0)
Compound 451238 (0)
DB-1202 (0)
DR-01 (0)
FL-496 (0)
GS-168 (0)
HRS-2189 (0)
HS-10386 (0)
K-001 (0)
LEAC-102 (0)
MK-0472 (0)
OT-A201 (0)
PM54 (0)
QLS1103 (0)
QLS31903 (0)
ROSE12 (0)
SBS-101 (0)
SPYK04 (0)
Undisclosed immune evasion therapeutic (0)
Undisclosed masked antibodies (0)
WJB001 (0)
compound 121564 (0)
mRNA-2736 (0)
SQ-001 (0)
BL0020 (0)
Compound 451238 (0)
DB-1202 (0)
DR-01 (0)
FL-496 (0)
GS-168 (0)
HRS-2189 (0)
HS-10386 (0)
K-001 (0)
LEAC-102 (0)
MK-0472 (0)
OT-A201 (0)
PM54 (0)
QLS1103 (0)
QLS31903 (0)
ROSE12 (0)
SBS-101 (0)
SPYK04 (0)
Undisclosed immune evasion therapeutic (0)
Undisclosed masked antibodies (0)
WJB001 (0)
compound 121564 (0)
mRNA-2736 (0)
SQ-001 (0)
›
Associations
News
Trials
Filter by
Latest
over1year
A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=50, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
over 1 year ago
New P1 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
QLS12004
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login